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Summary. Two sublines, the hormone-sensitive LNCaP- 
FGC and the insensitive LNCaP-r (resistant) carcinoma 
cell lines, originating from the parental human prostatic 
carcinoma cell line LNCaP were tested for sensitivity to 
human tumor necrosis factor-or (TNF) using the MTT 
assay. Irrespective of the culture conditions, i.e., whether 
FGC cell growth was hormone stimulated or hormone 
deprived, a clear dose-related response was observed 
between the concentration f TNF (range: 5-5000 U/ml) 
in the culture medium and the percentage of growth 
inhibition. In medium containing androgen-depleted 
serum, in which FGC cells showed reduced proliferative 
activity, the percentage ofinhibition by a concentration f 
100 U/ml TNF was substantially higher than that found in 
hormone-stimulated c lls (90 % and 60 %, respectively). In
contrast to the FGC cells, the hormone-insensitive 
LNCaP-r cells were almost completely resistant to the 
action of TNF. Growth of the FGC cells was almost 
completely inhibited, whereas growth of the LNCaP-r 
cells was retarded with only 20% at dosages up to 5000 
U/ml. This substantial difference in TNF responsiveness 
could not be ascribed to differences in TNF-binding 
capacity, as both the FGC and LNCaP-r cells were found 
to contain identical numbers of TNF-receptors (approxi- 
mately 1000 sites/cell). A possible association between 
hormone responsiveness and TNF sensitivity issuggested 
for these LNCaP sublines. 
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Ever since Huggins' and Hodges' report on the androgen 
dependence of prostate carcinoma, androgen ablation 
therapy has remained the treatment of choice for ad- 
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vanced prostate neoplasia [17, 31]. Most patients with 
advanced prostate cancer can be symptomatically im- 
proved by anti-androgen therapy. This approach is not 
curative, however, and the patient will ultimately suc- 
cumb to the progression of disease unresponsive to 
hormones [ 18] and resistant to current therapeutic modal- 
ities. As a result, prostate cancer continues to be the 
second cause of death from cancer in men [28]. 
Significant improvements in the efficacy of experimen- 
tal cancer therapies have been made by utilization of 
biological response modifiers [1-3]. TNF is a well- 
characterized secretory product of macrophages, which 
has shown direct antitumor activity in vivo as well as in 
vitro [11, 12]. The potential ofimmunotherapy, specifical- 
ly with TNF, in the treatment ofadvanced prostate cancer 
has received limited attention. 
Among the small number of permanent in vitro cell 
lines of human prostate cancer described up to now, the 
LNCaP (lymph node carcinoma of the prostate) cell line, 
developed by Horoszewicz [15], is the only model with 
androgen-responsive growth [16]. LNCaP cells secrete 
prostatic acid phosphatase and prostate-specific antigen; 
the cells also contain considerable amounts of androgen 
receptors [4] and have been shown to secrete polypeptide 
growth factors, such as epidermal growth factor (EGF) 
and transforming rowth factor-c~ [8]. Propagation of 
LNCaP cell cultures has led to the development of a 
number of sublines with different patterns of hormone 
responsiveness. These sublines descended from the par- 
ental LNCaP line either spontaneously or by maintenance 
of the original cell line in medium with steroid-depleted 
serum. An example is the spontaneous androgen-insensi- 
tive LNCaP-r (resistant) subline, which has been deve- 
loped and further characterized byHasenson et al. [13]. 
The efficacy of TNF in the therapy of experimental 
prostatic arcinomas, including the LNCaP cell line, has 
been reported by some investigators [10, 23, 27]. In the 
present study, the anti-proliferative activity of human 
TNF was determined in untreated and in hormone- 
deprived, androgen-responsive andunresponsive sublines 
of the LNCaP model. 
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Materials and methods 
Cell lines 
The LNCaP cell line was derived from culture explants of needle 
biopsy material from a lymph-node metastasis of a prostate cancer 
patient [15]. The LNCaP-FGC cell line descended from a fast- 
growing colony of the original LNCaP cultures [29]. This line was 
kindly made available to us by Dr. Horoszewicz (Buffalo, 
N. Y. USA) and was transferred toour laboratory as a 16th-passage 
culture. Another subline of LNCaP, designated LNCaP-r, was 
kindly provided by Dr. Hasenson (Huddinge, Sweden). LNCaP- 
FGC cells cultured in our laboratory for longer periods of time (5 
months) in androgen-depleted medium (see next paragraph) are 
designated FGC-DCC [30]. 
After exposing the cells to experimental media for 5 days, the cells 
were pulsed with MTT, incubated for 4 h, the plates processed and 
the absorbance (OD) detected, as described by Romijn et al. [25]. 
Eight replicate wells were used for each experimental condition. The 
percentage of relative survival fraction was determined on the basis 
of day 0 using the formula: Relative survival fraction = (ODtreate d - 
ODday 0/ODcontrol - ODday 0) X 100. 
TNF receptor assay 
For TNF-binding studies, TNF was radiolabeled according to the 
method of Bolton and Hunter [5]. The number of TNF receptors was 
estimated as whole cells, using a 125 I-TNF competitive ligand assay, 
as described by Budel et al. for IL-3 and GM-CSF [7]. 
Cell culture 
Both the LNCaP-FGC and LNCaP-r lines were routinely main- 
tained as monolayer cultures in RPMI 1640 medium (Gibco, Life 
Technologies Ltd., Paisly; U.K0 supplemented with;5 % fetalbovine 
serum (FBS; Hyclone, Greiner, Alphen a/d Rijn, The Netherlands), 
2 mM L-glutamine, 100 units/ml penicillin and 100 gg/ml strepto- 
mycin. LNCaP-FGC cells were also grown for longer periods of time 
(up to 5 months) in medium containing 5 % dextran-coated charcoal 
(DCC; dextran 0.1%, charcoal 1%) treated (i.e., steroid-depleted) 
serum. Untreated (FBS) serum contained 0.5-1.0 nM of testosterone 
(T), whereas in DCC serum less than 0.1 nM of T (the detection limit 
of the assay) was estimated. All cultures were grown in 25 cm 2 plastic 
tissue culture flasks (Falcon, Oxnard, Calif,) and kept in a 5% CO2- 
humidified air incubator at 37 ~ C. Cells were subcultivated at weekly 
intervals using a mixture of 0.05% trypsin and 0.02% EDTA. 
Tumor necrosis factor 
Recombinant human TNF-o, was kindly provided by BASF/Knoll 
AG (Ludwigshafen, FRG) and had a specific activity of 8.74 X 106 
U/rag protein, as measured on L929 cells in the absence of 
actinomycin D. TNF was dissolved in phosphate-buffered saline 
(PBS) plus 0.03% bovine serum albumin (BSA), aliquoted and 
stored at --80~ 
Cell proliferation assay 
Evaluation of the effects of androgens or TNF on the growth of the 
LNCaP cells was performed using a test system based on the 
enzymatic reduction of the tetrazolium salt MTT [3-(4,5-dimethyl- 
thiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide] [24]. This prolifer- 
ation assay was previously described as being suitable for the 
assessment of hormone-stimulated growth of the LNCaP cell line 
[25]. Cells harvested from routine cultures were suspended inRPMI 
1640 plus 5 % FBS and plated into 96-well flat-bottom icrotiter 
plates (Costar, Cambride, Mass.) at a density of 5 X 103 cells/well in 
a volume of 0.1 ml. After plating and incubation of the cells for 24 h 
to allow for attachment (day 0), serial diluted TNF-containing 
media were added to the wells in the volume of 0.1 ml/well to give a 
final concentration fTNF in the range of 5-5000 U/ml. 
To determine the response of the LNCaP cells to androgens, cells 
were pretreated for 3 days in medium containing 5% DCC serum, 
after which the medium was replaced by either the same medium or 
medium containing FBS, with or without he addition of 0.1 nM of 
the synthetic, non-metabolizable [6] androgen R 1881 (New England 
Nuclear, Boston, Mass.) to the respective media. 
Statistics 
The significance of differences between values of different groups 
was calculated using the two-tailed Student's t-test. 
Results 
Androgen responsiveness ofLNCaP cells 
It has previously been demonstrated that LNCaP-FGC 
cells can opt imal ly  be st imulated at a concentrat ion of  0.1 
nM R 1881, the levels reached being slightly lower than the 
cells grown in control  (FBS) serum [30]. F igure 1 shows 
the result of an experiment in which the androgen 
responsiveness of the LNCaP-FGC line was compared to 
that of the LNCaP-r  line. Over a per iod of 5 days, the 
growth of  the FGC and r cells was st imulated (3.2 and 4.5- 
fold, respectively) when cultured in DCC medium. In 
contrast to the FGC cells, however, the LNCaP-r  cells 
could not be signif icantly further st imulated by DCC 
medium with R 1881 (0.1 nM), or by medium containing 
normal  (FBS) serum (Fig. 1 B). In fact, the LNCaP-r  cells 
could be grown equally well in medium with DCC,  DCC 
+ R1881, or FBS. 
LNCaP-FGC cells that were cont inuously grown in 
DCC medium did not die, but their growth rate was 
clearly retarded. Such cultures could be mainta ined for 
long per iods of  time and, therefore, were considered a
separate subline, designated FGC-DCC.  Cells of this 
subline cultured for several months were still sensitive for 
androgens (i.e., R 1881) [30]. 
Response of androgen-sensitive and insensitive cells to TNF 
Growth of androgen-sensit ive LNCaP-FGC cells was 
signif icantly inhibited by TNF  (Fig. 2). A clear dose- 
response relat ionship was observed between the concen- 
trat ion of TNF  (5-5000 U/ml )  in the culture medium and 
the percentage of growth inhibit ion. A l though there was 
some variat ion between the various experiments per- 
formed, the median TNF  dose for the LNCaP-FGC cell 
was est imated at 50 U/ml.  In contrast,  the LNCaP-r  line 
appeared to be highly resistant to TNF. At  dosages of up 
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Fig. 1 A, B. Growth of LNCaP-FGC cells (A) and LNCaP-r cells (B) 
in complete (FBS) and androgen-depleted (DCC) medium with and 
without he synthetic androgen R 18 81. Values represent mean + SD; 
growth stimulation factor compared to DCC group is indicated at 
the top of each bar. Results were evaluated using MTT assay (for 
details, see Materials and methods ection) 
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Fig. 2. Response of the LNCaP-FGC and LNCaP-r cells to various 
concentrations of human TNF-c~. Cells were grown in the presence 
of 5% FBS and exposed to TNF for 5 days 
to 5000 U/ml of TNF, growth of the FGC cells was almost 
completely abolished, whereas growth of the LNCaP-r 
ceils was inhibited by only 20% (Fig. 2). Both the LNCaP- 
FGC and LNCaP-r cells contain identical numbers of 
TNF receptors, the concentration being estimated at1000 
sites/cell (data not shown). 
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Fig. 3A-C. TNF responsiveness of LNCaP-FGC (A), FGC-DCC (B) 
and LNCaP-r (C) cells grown under the condition of steroid- 
depleted (DCC) medium (77) or DCC medium supplemented with 
0.1 nM R1881 (ll) 
Effect of androgen-depletion on TNF responsiveness 
Figure 3 shows the result of a TNF dose-response exper- 
iment with LNCaP-FGC, FGC-DCC and LNCaP-r cells 
either grown in DCC medium or in DCC medium with 
androgen (R1881). LNCaP-FGC cells grown in andro- 
gen-depleted (DCC) medium showed reduced prolifera- 
tive activity (Fig. 1) and appeared to be significantly 
(P<0.001) more sensitive to TNF in comparison to cells 
stimulated with the androgen R1881 (Fig. 3A). When 
optimally grown LNCaP-FGC cells are stimulated by 
serum or by androgens, the response isapparently similar 
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with either dose of TNF (cf. Figs. 2 and 3A). The TNF 
response pattern was found to be about the same with 
FGC-DCC cells, i.e., LNCaP-FGC cells that were de- 
prived of androgens for several months (Fig. 3B). TNF 
treatment of LNCaP-r cells cultured in DCC medium 
resulted in a maximal inhibition of 25%, which was 
comparable to the result obtained with cells grown in FBS 
medium (cf. Fig. 2), whereas R1881 induced a further 
resistance to TNF (Fig. 3 C). Over the whole range of TNF 
used, a statistically (P < 0.001) significant difference in the 
percentage of inhibition was found between cells cultured 
in DCC medium and in medium with R1881 (Fig. 3C). 
Discussion 
Human cancer of the prostate isa complex disease and the 
study of several aspects of this type of cancer can only be 
investigated by the use of appropriate animal and in vitro 
systems. In spite of the efforts of many investigators to 
establish in vitro cultures of prostate pithelium, only a 
limited number of continuously growing cell lines of 
human prostate carcinoma has been developed. TNF is a 
macrophage/monocyte secretory product that plays an 
important role in host-mediated antitumor defence and 
the pathophysiological response to sepsis and neoplasia. 
TNF is directly cytotoxic to numerous tumor cell lines in 
vitro, but in general normal cells are resistant to TNF- 
mediated cytolysis [12]. 
In the present study it was demonstrated that LNCaP- 
FGC cells are highly sensitive for the anti-proliferative 
effects of TNF (Fig. 2). This result has been demonstrated 
before by other investigators [10, 27], but in these studies 
the possibility of combining hormone treatment, i.e., 
androgen withdrawal, and TNF therapy was not con- 
sidered. In a previous tudy on the LNCaP cell line in our 
laboratory, it was shown that the LNCaP-FGC subline, 
which shares all the properties of the parental LNCaP cell 
line, including its androgen responsiveness, can be grown 
at a slow growth rate in androgen-depleted medium [30]. 
Under the condition of androgen-deprived growth of the 
LNCaP-FGC line, the cells appeared to be more suscep- 
tible to the antitumor effects of TNF in comparison with 
optimally growing LNCaP cultures (Fig. 3 A). In addition, 
it was observed that long-term cultures of LNCaP-FGC 
cells in androgen depleted medium, did not lead to major 
changes in either the androgen responsiveness, or the 
inhibitory effect of TNF (Fig. 3B). For ventral prostate 
cells of the rat and for prostate carcinoma cells, it has been 
shown that androgen deprivation i duces apoptosis [21], 
and TNF is also described as triggering this process in 
various cell types such as lymphocytes [26]. It is tempting 
to speculate that in the androgen-responsive LNCaP cells, 
TNF and anti-androgenic (e.g., androgen withdrawal) 
treatment act synergistically in the induction of apoptosis 
in these cells. This possibility is currently being investigat- 
ed. 
The LNCaP-r line emerged irectly from the parental 
LNCaP cell line, as in a cytogenetic study by K6nig et al. it 
was clearly demonstrated that the LNCaP-r subline had 
the same basic karyotype in common with the original 
LNCaP line, including some new, subline-specific marker 
chromosomes [20]. LNCaP-FGC and-r cells differ in their 
responsiveness to estramustine, a compound used for the 
treatment of prostate carcinoma [14, 19]. In contrast o 
LNCaP-FGC cells which were shown to be inhibited with 
70% by TNF at a dose of 50 U/ml, the LNCaP-r cells 
appeared to be highly resistant to TNF (Fig. 2). Growth of 
the androgen-unresponsive LNCaP-r cells was retarded 
with only 20% at dosages of up to 5000 U/ml. This 
substantial difference in TNF responsiveness could not be 
ascribed to dissimilarities in TNF binding capacity, as 
both the LNCaP-FGC and r cells were found to contain 
identical numbers of TNF receptors. This strongly sug- 
gests that TNF responsiveness in the LNCaP cell line is 
expressed at a post-receptor level. This has also been 
demonstrated for other cell lines, such as the ME-180 
cervical tumor cell line [9]. At the post-receptor level, i.e., 
intracellularly, several pathways are known to be involved 
[22] in TNF signal transduction, although many uncer- 
tainties remain in this respect. Major steps in the TNF- 
mediated cytotoxicity cascade include G-protein-coupled 
activation of phospholipases, generation of free radicals, 
and damage to nuclear DNA by endonucleases. Ultimate- 
ly, the cells undergo apoptosis (see above) and die. 
Conflicting data have been reported on the response of 
the hormone-independent prostate cancer cell line, PC-3. 
In a study by Sherwood et al. [27], the LNCaP cell line and 
hormone-independent PC-3 and DU-145 prostate carci- 
noma lines have all been found to be sensitive for the 
antitumor effect of TNF, as confirmed for the PC-3 cell in 
a study of Liu et al. [23]. In contrast, Fruehauf et al. [10] 
found the PC-3 cell to be highly resistant to TNF, and in 
their study the sensitivity of the LNCaP cell line was also 
confirmed. Generally, the number of prostate cell lines 
with different patterns of hormone sensitivity is too 
limited to allow conclusions to be made on the possible 
association between androgen and TNF responsiveness. 
As far as the LNCaP model is concerned, however, the 
present results with the FGC and r sublines suggest a 
possible association between hormone responsiveness and 
TNF sensitivity. Consequently, as far as the possible 
application of TNF to clinical prostate cancer is con- 
cerned, the results with in vitro LNCaP cell lines do not 
indicate that therapeutic ntervention with this cytokine 
would be helpful in progressive, hormone-independent 
prostate carcinoma. The approach in which TNF is 
applied in combination with anti-androgen therapy in 
hormone-responsive prostate cancer seems in this respect 
more promising. More experimental studies are necessary 
with in vitro cell lines but, more importantly, with in vivo 
models, such as transplantable human prostatic arcino- 
mas in athymic nude mice. 
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